Ibio, INC. (IBIO) SEC Filings — 2025
21 SEC filings for Ibio, INC. (IBIO) in 2025.
Filings
- iBio, Inc. Submits Matters to Security Holders — 8-K · Nov 21, 2025
- iBio's Q1 Loss Widens to $5.7M, Cash Reserves Jump Post-$50M Offering — 10-Q/A · Nov 17, 2025
- iBio's R&D Surge Drives Wider Loss, Bolstered by $50M Capital Raise — 10-Q · Nov 12, 2025
- iBio, Inc. Files 8-K Report — 8-K · Nov 4, 2025
- iBio, Inc. Files 8-K Report — 8-K · Oct 30, 2025
- iBio Sets 2025 Annual Meeting: Director Elections, Auditor Ratification on Docket — DEF 14A · Oct 6, 2025
- iBio Raises $46.5M, Advances Obesity Pipeline with AI-Driven Antibodies — 10-K · Sep 5, 2025
- iBio, Inc. Files 8-K: Material Agreement & Disclosures — 8-K · Aug 21, 2025
- iBio, Inc. Files 8-K with Financial Updates — 8-K · Aug 18, 2025
- iBio Faces NYSE American Delisting Threat — 8-K · Aug 1, 2025
- iBio, Inc. Files 8-K with Regulatory Disclosures — 8-K · Jun 24, 2025
- iBio, Inc. Files 8-K Report — 8-K · Jun 18, 2025
- iBio, Inc. Q3 2025: Revenue $0.22M, Net Loss $2.25M — 10-Q · May 2, 2025
- iBio, Inc. Files 8-K: Material Agreement, Exhibits — 8-K · Apr 22, 2025
- iBio, Inc. Files 8-K Report — 8-K · Apr 8, 2025
- iBio, Inc. Files 8-K Report — 8-K · Apr 7, 2025
- iBio Faces NYSE American Delisting Risk — 8-K · Feb 19, 2025
- iBio, Inc. Q2 2025: Assets $9.1M, Liabilities $1.9M — 10-Q · Feb 10, 2025
- iBio, Inc. Files 8-K: Material Agreement, Equity Sales — 8-K · Jan 13, 2025
- iBio, Inc. Files 8-K Report — 8-K · Jan 10, 2025
- iBio, Inc. Files 8-K with Material Agreements and Equity Sales — 8-K · Jan 2, 2025